News 2/6/17
Entest BioMedical Inc.s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche
Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which Include Arthritis
Entest BioMedical Inc.'s (OTCPINK: ENTB) Zander Therapeutics subsidiary has added Harry Lander, PhD, MBA as its President and Chief Scientific Officer and Todd S. Caven as its Chief Financial Officer. Thomas Ichim, PhD will assist the company as its Senior Scientific Consultant and Debbie Dorsee will serve as Director of Business Development.
Zander Therapeutics Inc. is focused on the rapidly growing veterinary medicine market niche. In 2016, the U.S. pet market was estimated to be $62.75 billion dollars in size, which is up from $38.5 billion in 2006 and $48.53 billion in 2010. Out of $62.75 billion, $16 billion was spent on veterinary care alone.
Lander has over 25 years of professional scientific, business and financial management experience related to biomedical research. He has a deep knowledge of operations and research administration. . He has extensive relationships with large and small biotechnology and pharmacology expects to leverage for company growth. He has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University) and served as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University).
Caven has 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. He co-founded Saguaro Capital Partners, an Arizona-based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States. Caven also founded Rock Ridge Enterprises, a Minnesota-based boutique private equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Formerly, Caven served as CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately-held firm in the staffing and recruiting industry. He also held senior-level finance and marketing positions at Nordic Track and the Carlson Companies., both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum). Caven earned a bachelor's degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Dr. Ichim has 20 years of biotechnology experience, including founding Immune Advisors LLC, a biotechnology consulting group focused on accelerating commercialization of companies in the regenerative medicine and immune-oncology space. Dr. Ichim previously served as Chief Scientific Officer and Chief Executive Officer of Medistem Inc. which was acquired by Intrexon Inc. He also co-founded bioRASI (a contract research organization), served as a Vice President of Cellular Therapies at Intrexon Inc. Dr. Ichim has more than 100 peer reviewed publications on cell therapy and immunology and over 100 patents and patent applications.
Debbie Dorsee is the founder and principal executive of The Dorsee Company, a leader in public relations for businesses and individuals both regionally and nationally. She has an integrated focus on community relations, marketing, fundraising / capital raising and business development. Dorsee received the San Diego North Chamber of Commerce's Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine's Metro Movers to Watch.
Zander's Chairman & CEO David Koos noted, "With the addition of these new management team members, Zander is poised to advance its business model rapidly. We have both proprietary intellectual property and licensed intellectual property (from Regen BioPharma Inc.), which are aimed at addressing maladies suffered by our pets through the development of small molecule therapies. The veterinary market is something I'm extremely passionate about, as I have two basset hounds and lost my first basset hound to cancer. I'm excited that Zander can provide therapies that prevent the suffering of our pets."
